IL15 and neoplasm: On the other hand, the emergence of antigen-negative tumor relapse indicates that treatment with H9 CAR-IL15 T cells in current regimens did not induce an effective host endogenous immune reaction to tumor cells independent of the targeted antigen in most treated mice, which is also concordant with our observation of minor changes in host immune cells in those mice.